By Emily Ledger
Raw Biotech Plc is setting its sights on becoming one of the next generations of seed-to-consumer companies in the fast-growing medical cannabis and CBD wellness sectors.
Having spent the last two years building up its management and scientific teams and studying the early movers in this space has enabled the company to strategically identify the real opportunities.
“We believe that the best investment we can make is bringing in the expertise of people who can study the industry and watch how the regulatory landscape evolves.
“We are committed to getting things 100% right, especially as we are investing our own money to the company’s start. This approach has allowed us to carefully select the right companies to invest in and, where necessary, identify gaps in the market to create our own,” said Kevin Du Plessis, Raw Biotech Plc CEO.
It’s probably no surprise the private equity company’s first major investment is in Switzerland, which has fast become the centre of the EU CBD industry, with its well-developed domestic market and regulatory framework. Raw Biotech Plc has made an investment in the Canton of Ticino to develop a GMP-certified CBD extraction and manufacturing facility alongside indoor and outdoor cultivation of hemp for CBD and pharmaceutical products.
Parallel to this is a medical research and development division which is currently working with strategic partners to deliver a range of patented medical products to market:
“It’s important to us and, in fact, a business priority in today’s global cannabinoid markets that we are in a position to create our own products from the ground up, at every level of the supply chain.
“In our industry, this is the only way to guarantee the source and quality of products to pharmaceutical companies, wellness brands and consumers. Our first investment had to be multi-level for this reason. We are utilising blockchain to validate our supply chain and show full transparency and certifications each step of the way. This is something that very few companies are able to do.
“We believe consumers and regulators are starting to demand transparency and this is clearly the future. Our investment in Switzerland represents the start of our investment and development program with further acquisitions already in process,” said Du Plessis.
Raw Biotech Plc presently has secured €6 million to facilitate its initial investments into the CBD and cannabis sector and is planning a future expansion on the back of its own successful business operations and acquisition or investment into other strategic companies in the supply chain.